Coronary artery disease (CAD) is a leading cardiovascular condition caused by plaque buildup in the arteries, restricting blood flow to the heart. In 2022, there were approximately 315 million prevalent cases of coronary artery disease. There is a high unmet clinical need for better therapies, as current treatment options, such as statins and antiplatelet drugs, have limitations. The growing focus on novel coronary artery disease therapeutics, including PCSK9 inhibitors, anti-inflammatory agents, and regenerative therapies, is likely to drive pipeline growth. Advancements in personalized medicine and gene therapies further offer promising avenues for developing innovative coronary artery disease drug candidates.
Major companies involved in the coronary artery disease pipeline drug market include Novartis Pharmaceuticals, Honya Medical Inc., and others.
Leading drugs currently in the pipeline include Inclisiran sodium 300 mg, RBD4059, VERVE-102, and others.
With the rising advancements in targeted therapies, including PCSK9 inhibitors, anti-inflammatory agents, gene therapies, and regenerative medicine, the coronary artery disease drug pipeline is expected to expand rapidly.
The Coronary Artery Disease Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into coronary artery disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for coronary artery disease. The coronary artery disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The coronary artery disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with coronary artery disease treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to coronary artery disease.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Coronary artery disease (CAD) occurs when plaque builds up in the coronary arteries, narrowing and hardening them, which limits blood flow to the heart. This condition often results from atherosclerosis, where fatty deposits, cholesterol, and other substances accumulate on the artery walls. It can lead to chest pain, heart attacks, or other serious cardiovascular complications.
Coronary artery disease treatment typically includes lifestyle changes, medications like statins and antiplatelet drugs, and in severe cases, surgical procedures such as angioplasty or coronary artery bypass surgery. These therapies aim to reduce symptoms, prevent complications, and improve heart function.
According to a study, in 2022, approximately 315 million people globally were affected by coronary artery disease (CAD), with notable regional variations. Central and Eastern Europe, along with Central Asia, exhibited high age-standardized prevalence (8,019 per 100,000). In the United States, coronary artery disease remains the most common heart disease, causing 371,506 deaths in 2022, with around 5% of adults impacted.
This section of the report covers the analysis of coronary artery disease drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase IV covers a major share of the total coronary artery disease clinical trials.
The drug molecule categories covered under the coronary artery disease pipeline analysis include small molecules, monoclonal antibodies, peptides, gene therapies, and RNA-based therapies. The coronary artery disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for coronary artery disease.
The EMR report for the coronary artery disease drug pipeline covers the profiles of key companies involved in clinical trials and their drugs under development. It provides a detailed coronary artery disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in coronary artery disease clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for coronary artery disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of coronary artery disease drug candidates.
Novartis Pharmaceuticals is sponsoring a Phase IIIb study to evaluate Inclisiran’s efficacy in reducing atherosclerotic plaque progression in coronary artery disease patients. The study aims to assess plaque reduction through coronary computed tomography angiography (CCTA) over 24 months. Expected to be completed by January 2027, it includes approximately 608 participants receiving Inclisiran or placebo alongside statin therapy.
The Phase IIa clinical trial, sponsored by Ribocure Pharmaceuticals AB, aims to evaluate the safety, pharmacokinetics, and pharmacodynamics of RBD4059 in participants with stable coronary artery disease. The study will assess potential side effects and efficacy compared to a placebo. With an estimated enrollment of 30 participants, the trial is expected to conclude by December 31, 2025.
Verve Therapeutics, Inc. is sponsoring a Phase 1b clinical study, evaluating the safety of VERVE-102 in patients with heterozygous familial hypercholesterolemia or premature coronary artery disease. The study aims to assess the drug's safety and pharmacodynamic profile by utilizing base-editing technology to disrupt the PCSK9 gene expression in the liver. The study is expected to be completed by August 2026 with an enrollment of around 36 participants.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Coronary Artery Disease Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for coronary artery disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into coronary artery disease collaborations, regulatory environments, and potential growth opportunities.
Global Acute Coronary Syndrome Treatment Market
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share